You are here: Industry Insights > SARS-CoV-2

News List

SARS-CoV-2 Antigen Test Kit Receives CE Certification americanpharmaceuticalreview
December 22, 2020
Beroni Group has received notification from its European Authorized Representative, CMC Medical Devices & Drugs SL, that its newly developed SARS-CoV-2 Antigen Test Kit (Colloidal Gold Method) complies with the applicable essential requirements of the ...
UK identifies new SARS-CoV-2 strain that spreads faster pharmaceutical-technology
December 22, 2020
The UK has identified a new variant of Covid-19 through Public Health England’s genomic surveillance and confirmed that it could spread faster.
Neutralizing antibodies protect against severe COVID-19 worldpharmanews
December 21, 2020
Understanding the body's immune response to SARS-CoV-2, the virus that causes COVID-19, is key to developing effective treatments and long-lasting vaccines.
ACE2 protein protects against severe COVID-19 worldpharmanews
December 18, 2020
Female COVID-19 patients face less severe disease complications and a lower risk of dying than male patients thanks to hormones and chromosomes that contribute to a stronger immune response, according to new research from a University of Alberta-led team.
International consortium creates ‘open platform’ for COVID-19 drug discovery pharmatimes
December 18, 2020
An international consortium, led by Cambridge Medical Research Council (MRC) researchers, has developed an ‘open platform’ to advance and prioritise drug discovery and repurposing efforts for COVID-19.
Remdesivir likely to be highly effective antiviral against SARS-CoV-2 worldpharmanews
December 16, 2020
The drug remdesivir is likely to be a highly effective antiviral against SARS-CoV-2, according to a new study by a team of UK scientists.
Eureka Therapeutics’ nasal spray protects against Covid-19 in studies pharmaceutical-technology
December 16, 2020
Eureka Therapeutics has announced that preclinical results of its InvisiMask Human Antibody Nasal Spray in mice showed it offers up to ten hours protection against SARS-CoV-2 S pseudotyped virus infection.
Harbour BioMed and Utrecht University Announce License Agreement with AbbVie and Initiation of COVID-19 Antibody Clinical Trials prnasia
December 15, 2020
Harbour BioMed (HBM), and Utrecht University (UU) today announced that they licensed to AbbVie their fully human, SARS-CoV-2 neutralizing antibody, 47D11 and program, for the prevention and treatment of COVID-19 and related coronaviruses, and that ...
Anixa, OntoChem COVID-19 Therapy Demonstrates Comparable Potency to Remdesivir americanpharmaceuticalreview
December 15, 2020
Anixa Biosciences and OntoChem GmbH have verified one of their recently discovered compounds is similar in potency to remdesivir, the only approved anti-viral drug against SARS-Cov-2. As previously announced, Anixa and OntoChem had identified multiple ...
FDA takes key action in fight against COVID-19 by issuing Emergency Use Authorization for first COVID-19 vaccine worldpharmanews
December 14, 2020
The U.S. Food and Drug Administration issued the first emergency use authorization (EUA) for a vaccine for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 16 ...

Previous page 1 2 3 4 5 6 7 8 9 10 ... 61 62 Next page